Antimicrobial resistance represents a public health problem with a major negative impact on health and socioeconomic development, and is one of the biggest threats in the modern era. This requires the discovery of new approaches to control microbial infections. Nanomedicine could be one of the promising strategies to improve the treatment of microbial infections. Polymer nanoparticles (PNPs) were reported to overcome the efflux-resistant mechanism toward chemotherapeutic agents. However, to the best of our knowledge, no studies were performed to explore their ability to overcome the efflux-resistant mechanism in bacteria. In the current study, azithromycin (AZI), a macrolide antibiotic, was encapsulated into a biocompatible polymer, poly (lactic-co-glycolic acid) (PLGA) using the nano-precipitation method. The effect of the drug to polymer ratio, surfactant, and pH of the aqueous medium on particle size and drug loading percentage (DL%) were investigated in order to maximize the DL% and control the size of NPs to be around 100 nm. The antibacterial activity of AZI-PLGA NPs was investigated against AZI-resistant bacteria; Methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis (E. faecalis), where the efflux mechanism was demonstrated to be one of the resistant mechanisms. AZI-PLGA NPs were safer than free AZI, as revealed from the cytotoxicity test, and were able to overcome the efflux-resistant mechanism, as revealed by decreasing the MIC of AZI-PLGA NPs by four times than free AZI. The MIC value reduced from 256 to 64 µg/mL and from >1000 to 256 µg/mL for MRSA and E. faecalis, respectively. Therefore, encapsulation of AZI into PNPs was shown to be a promising strategy to overcome the efflux-resistant mechanism towards AZI and improve its antibacterial effect. However, future investigations are necessary to explore the effect (if any) of particle size, surface charge, and material composition of PNPs on antibacterial activity. Moreover, it is essential to ascertain the safety profiles of these PNPs, the possibility of their large-scale manufacture, and if this concept could be extended to other antibiotics.
26 July 2021 in Journal of Advanced Pharmacy Research
Microbial infections have been the leading cause of death throughout history. This was changed when antibiotics were discovered, causing an increase in life expectancy from 48 years to 72 years. However, this golden era might end very soon. Bacteria have evolved resistance against antibiotics using different pathways. Therefore, restrictive policies about using antibiotics should be implemented by the healthcare system to prevent the further spread of bacterial resistance. However, these policies might not be enough without discovering or synthesizing new antibiotics. Antibiotics synthesis or discovery is a lengthy, tedious multistage process. Moreover, the development of bacterial resistance against any newly developed antibiotics takes around 10 years. Therefore, there is a need to find another strategy to retain the current available antibiotics activity against micro-organisms. Nanotechnology is a cutting-edge science that has been emerged few decades ago, it is concerned with producing fibers or particles in the nanometer scale. In literatures, nanoparticles were shown to improve the drug solubility, bioavailability, modify drug pharmacokinetics, increase drug stability, target drug into certain sites and moreover, were proven to overcome some developed resistance mechanisms against anticancer drug (e.g. Efflux mechanism). Recently, nanotechnology techniques have been applied to combat microbial infections and they were proven to be able to overcome the bacterial developing resistance mechanism. In this review, we are presenting a historical background of antibiotics and discussing some bacterial developed resistance mechanisms as well as stating different nano-based formulations that were developed and proved to be effectively potentiate the antibiotic activity against some resistant micro-organisms.
1 December 2025 in Journal of Mass Spectrometry and Advances in the Clinical Lab
Mass spectrometry is a powerful technique for tear fluid proteomics, offering critical insights into its complex molecular composition. Traditional data-dependent acquisition (DDA) often favors high-abundance proteins because it selects only the most intense precursor ions within a given window during each scan cycle. A newer approach, data-independent acquisition (DIA), addresses this by fragmenting all precursor ions within defined mass windows, offering broader coverage and improved quantification. This study presents a systematic comparison of DDA and DIA workflows to assess their relative performance in detecting tear fluid proteins. Tear fluid samples were collected from healthy individuals using Schirmer strips, processed using in-strip protein digestion, and analyzed via liquid chromatography-tandem mass spectrometry (LC-MS/MS). DDA and DIA workflows were compared for proteomic depth, reproducibility, and data completeness. Quantification accuracy was assessed using serial dilutions of tear fluid in a complex biological matrix. DIA identified 701 unique proteins and 2,444 peptides, outperforming DDA, which identified 396 unique proteins and 1,447 peptides. Across eight replicates, DIA exhibited greater data completeness (78.7% for proteins and 78.5% for peptides) compared with DDA (42% for proteins and 48% for peptides). Reproducibility was markedly improved with DIA, with a median coefficient of variation (CV) of 9.8% for proteins and 10.6% for peptides, compared to 17.3% and 22.3%, respectively, for DDA. Quantification accuracy was also enhanced, with superior consistency across the dilution series. Overall, DIA provides deeper, more reproducible, and more accurate proteome profiling of tear fluid than DDA, making it well suited for biomarker discovery.